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Abstract
Background: The most common treatments for scabies in human and veterinary settings are topical 5%
permethrin or systemic treatment with ivermectin. However, these treatments have very little activity against
arthropod eggs, and therefore repeated treatment is frequently required. In-vitro, biochemical and molecular
studies have demonstrated that human mites are becoming increasingly resistant to both acaricides. To identify
alternate acaricides, we undertook a pilot study of the in vivo activity of the benzoylphenyl urea inhibitor of chitin
synthesis, fluazuron, in pigs with sarcoptic mange.
Findings: Pigs (n = 5) were infested with S. scabei var suis, and randomised to treatment at the start of peak
infestation with fluazuron at a dose of 10 mg/kg/day per os for 7 days (n = 3) or no treatment (n = 2). Clinical
scores, skin scrapings for mite counts and blood sampling for pharmacokinetic analysis were undertaken. Fluazuron
was well absorbed in treated pigs with measureable blood levels up to 4 weeks post treatment. No adverse effects
were observed. Modest acaricidal activity of the compound was observed, with a reduction in severity of skin
lesions in treated pigs, as well as a reduction in number of scabies mite’s early life stages.
Conclusions: The moderate efficacy of fluazuron against scabies mites indicates a lead to the development of
alternate treatments for scabies, such as combination therapies that maybe applicable for human use in the future.
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Findings
Scabies is an infectious skin disease caused by a micro-
scopic mite, Sarcoptes scabiei. The number of treat-
ments employed for this parasitic disease is very limited.
The most common treatments in human and veterinary
settings are topical 5% permethrin and/or systemic
treatment with a macrocyclic lactone, such as ivermectin
[1]. These acaricides have relatively little activity against
arthropod eggs, hence multiple treatments are generally
required to achieve cure. Using in-vitro, biochemical
and molecular approaches, we have previously demon-
strated that mites are becoming increasingly resistant to
both acaricides [2-4]. The emergence of acaricide
resistance in mites has highlighted the need to identify
new acaricidal agents. We have previously investigated
the acaricidal activity of natural product extracts of tea-
tree oil and clove oil and their active components using
in vitro studies of mites collected from pigs with experi-
mental scabies infestation [5]. These studies have shown
potential useful acaricidal activity of essential oils- tea-
tree (Melaleuca alternifola)a n dc l o v e( Eugenia caryo-
phyllata), and their active components [6,7].
Another approach to the development of acaricides
suitable for human use is to investigate the utility of
existing veterinary products with likely acaricidal activ-
ity. Commercially available veterinary acaricides include
Fipronil and Amitraz. These are effective treatments for
Sarcoptic mange in dogs and cats. Both disrupt function
of the nervous system of arthropods and cause a knock
down effect similar to that of pyrethroids and
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compounds act as acaricides in a different way, by
blocking the synthesis and deposition of chitin, thereby
preventing molting and sterilising eggs [8,9]. Earlier stu-
dies have shown that BPU compounds are active at low
concentrations against arthropods and have the poten-
tially useful property of a long-lasting, residual effect
[10-12]. Importantly they have high specificity, with low
mammalian toxicity [13].
Fluazuron is a BPU acarine growth inhibitor that is
marketed for the control of cattle tick, Rhipicephalus
microplus. As this compound inhibits specific enzymes
involved in moulting, drug-exposed immature ticks are
unable to moult to the next stage, and treated females
lay sterile eggs [14]. Flurazuron has also been used to
control fleas on wild rodents, woodrats and mice [15],
and as an oral/systemic acaricide to control ticks and
fleas of woodrats [16]. We conducted an exploratory
trial to assess the activity of orally administered flua-
zuron against Sarcoptes scabei infestation in pigs.
Methods
The study was approved by the Animal Ethics Com-
mittee (Approval number: SA 2010/11/335). Three-
week female, weaner pigs (Sus scrofa) were infected
with S. scabiei var suis maintained on a daily 0.2 mg/
kg dexamethasone as previously described [5] to
enhance infestation intensity. Prior to treatment, fort-
nightly skin scrapings were performed to monitor mite
number; the relative numbers of different life stages
were assessed during the course of infestation. Skin
crusting and lesions associated with mite infestation
were also monitored on a weekly basis using a scoring
system that we had developed in a previously pub-
lished study [5]: Scores of 1-8, where 1-3 indicates
acute, papular mange; 4 and above indicates crusts of
increasing severity [5]. As no relevant data were avail-
able to inform a power calculation for assigning study
size, for welfare and logistical reasons a study size of
six was set, with three pigs assigned to the treatment
and three to the control (untreated) group. One piglet
died unexpectedly of an unrelated cause before the
trial commenced. Hence, the remaining five pigs were
randomly allocated to treatment (n = 3) and untreated
control (n = 2) groups. The treatment and control pigs
were housed in separate rooms (in individual pens) of
the experimental animal holding facility of the Centre
for Advanced Animal Studies (CAAS) at UQ, Gatton
to prevent cross contamination. Fluazuron was admi-
nistered as an oral drench using a syringe simulta-
neously to the treatment group beginning 8 weeks
following mite infestation. At this point, skin lesions
were clinically evident in all trial pigs (Clinical scores
of 1-4). Baseline mite counts prior to treatment were
also obtained for each trial pig. An equal amount of
skin crusts (~ 0.15 grams), from skin lesions on the
back and ears of the trial pigs were collected, and the
number and life stages of mites were recorded. Com-
mercially formulated fluazuron (Acatak
® Novartis Ani-
mal Health, Macquarie Park, NSW) containing 25 mg/
ml fluazuron was given daily by mouth for 7 days at
0.4 ml/kg to give 10 mg/kg/day to the treatment
group. A 7-day regimen was selected for this first
study as the investigators were seeking to identify an
effect at a high dose regimen that could subsequently
be optimised. Blood samples (10 ml) were collected for
pharmacokinetic analysis 24 hours before treatment
(Day 0) and on Days 1, 2, 5, 7, 21 and 28 post treat-
ment. Serum levels of fluazuron were determined by
HPLC-UV (Waters Instrumentation, Ireland) using an
in-house fluazuron standard calibration curve. Skin
scrapings were collected from trial pigs, 2 and 7 weeks
post treatment to monitor mite status, numbers and
life stages. Skin crusting and lesions in all trial pigs
were also scored at the same time intervals. Pigs were
euthanased at the end of the study. No statistical infer-
ences were made because of limitations in sampling
from a small number of trial pigs.
Results
Fluazuron was quickly absorbed in three treated pigs,
with a rapid rise in blood levels 24 hours after oral
administration. Blood levels of fluazuron remained
detectable for 28 days after initiation of treatment (Fig-
ure 1A).
Clinical progression of the disease (in terms of lesion
+ crust scores) continued to rise from baseline (week 0)
in the control, untreated pigs (C6365 and C6366) reach-
ing a maximum at week 5 onwards, continuing to week
8 when the study was concluded. In contrast, progres-
sion of clinical score in the treated pigs was arrested up
to week 5 post treatment. However, after week 5, relapse
of the clinical symptoms of scabies in pigs Tx6360 and
Tx6367 was observed. Disease progression was totally
abrogated in Tx6362 pig. Of note, this pig had the high-
est blood level of fluazuron (Figure 1B).
From 2 weeks post treatment, a decline in overall mite
counts especially in early life stages was observed in two
fluazuron treated pigs (Tx6360 and Tx6362). This
reduction is expressed as a fold change of < 1 compared
to the baseline mite counts (set at 1) (Figure 2A and
2B). Tx6367 pig which had the lowest level of blood
fluazuron showed the slowest reduction in juvenile stage
mite counts with changes observed only on the 7th
week post treatment. Of note, the baseline mite burden
of this pig was heavy and the oral dosage (10 mg/kg)
used may not have been sufficient to kill all mites pre-
sent in the crusted skin. In comparison, the untreated
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compared to baseline from 2 weeks onwards.
Trial pigs were euthanased at the conclusion of the
study and no adverse effects of oral administration of
fluazuron was observed post mortem.
Discussion
Ivermectin is the only oral drug available to treat human
scabies. As it does not have activity against eggs,
repeated treatment is generally required, with the sec-
ond dose generally administered after 7-10 days [1]. A
single dose regimen that would target all life stages to
achieve complete cure would represent a major advan-
tage. Fluazuron represents a potential partner to iver-
mectin; it works well with cattle ticks and targets the
parasite’s early life stages. In a similar study, a mixture
of a juvenile hormone regulator (pyriproxyfen) and a
bioinsecticide (spinosad), has demonstrated effective
control of insecticide resistant Aedes aegypti [17].
As it is not possible to test the effect of Fluazuron
against the mite eggs in vitro, we conducted this in-vivo
trial in the mange pig model. We observed an effect on
the population structure of mites, with a decrease in
numbers of juvenile stages evident from 2 weeks post
treatment of trial pigs. Overall moderate efficacy was
observed, with arrest of clinical progression of scabies in
treated pigs until week 5. Although complete clearance
of lesions was not observed, a notable decrease in mite
counts was achieved (post treatment compared to base-
line) especially in juvenile stages in treated pigs. No
adverse effects of fluazuron on the pigs were observed
at necropsy examination.
The oral dose rate of 10 mg/kg/day resulted in peak
blood levels of 300 to 800 ng/mL (300 - 800 ug/L) flua-
zuron. This blood level in pigs is significantly higher
than those achieved in cattle following either pour-on
treatment (35 - 41 ug/L) or following subcutaneous
administration (100 ug/L) at a dose of 1.5 mg/kg [18].
However, in this study, the higher plasma level of flua-
zuron resulted in modest acaricidal activity, without
total clearance of the skin lesions. Unlike ticks, mites do
not ingest blood, and thus may have been exposed to
suboptimal fluazuron levels. This modest activity may
also be related to the in vivo pig model used (main-
tained on dexamethasone), which results in higher mite
numbers and more severe lesions than would be
observed in a natural infestation of scabies.
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Figure 1 (A) Fluazuron blood levels in trial pigs and (B) Clinical
presentation of trial pigs.
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Mite counts expressed as fold change from baseline where 1= no change in mite counts; < 1= 
reduction in mite counts and  > 1= increase in mite counts. 
Figure 2 Fold-change in mite counts in trial pigs in (A)
Juveniles and (B) All life stages.
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Page 3 of 4This exploratory study is the first in-vivo study to be
conducted to test acaricidal activity of an acarine growth
inhibitor (fluazuron) in scabies. This investigation paves
the way for studies aimed at exploring alternate treat-
ments for scabies, such as combination therapies, for
example, combination studies with drugs acting at dif-
ferent lifecycle stages. Such combinations may form the
basis of a treatment strategy applicable for human use
in the future.
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